Alexion Pharmaceuticals Q3 top line up 20%; non-GAAP EPS up 40%; raises revenue and non-GAAP EPS guidance

• Alexion Pharmaceuticals (ALXN) Q3 results: Revenues: $1,026.5M (+19.5%).
• Net Income: $330.9M; Non-GAAP Net Income: $460.1M (+40.1%); EPS: $1.47; Non-GAAP EPS: $2.02 (+40.3%).
• 2018 Guidance: Revenues: $4,020M - $4,050M from $3,980M - 4,010M; EPS: ($0.08) - 0.26 from $1.25 - 1.50; Non-GAAP EPS: $7.45 - 7.60 from $7.00 - 7.15.
• Shares are up 4% premarket.
• Previously: Alexion Pharmaceuticals beats by $0.28, beats on revenue (Oct. 24)